Skip to main content
SpringerLink
Log in

Eradikation des Hepatitis-C-Virus und Verhinderung klinischer Endpunkte

Eradication of hepatitis C virus and prevention of clinical endpoints

  • Schwerpunkt
  • Published:
Der Gastroenterologe Aims and scope

Zusammenfassung

Hintergrund

Die Hepatitis-C-Virus(HCV)-Infektion führt zu einem deutlich gesteigerten Risiko für klinische Komplikationen, wie Leberzirrhose und hepatozelluläre Karzinome, sowie zu einer erhöhten Mortalität.

Fragestellung

Welche Maßnahmen sollten zur Senkung der hohen HCV-assoziierten Morbiditäts- und Mortalitätsraten ergriffen werden?

Ergebnisse

Neue Modellrechnungen zeigen, dass beim Einsatz effektiverer Therapien und bei gesteigerten Behandlungsraten klinische Komplikationen einer HCV-Infektion verhindert werden können, die auch bei bereits vorliegender Leberzirrhose zu einer Reduktion der leberassoziierten Mortalität und Gesamtsterblichkeit führen. Gleichzeitig ist aber eine Intensivierung von HCV-Screeningprogrammen notwendig.

Schlussfolgerung

Bei einem konsequenten Einsatz neuer Behandlungsmethoden gegen HCV kann die HCV-assoziierte Krankheitslast in Deutschland in den nächsten 15 Jahren deutlich reduziert werden.

Abstract

Background

Hepatitis C virus (HCV) infection leads to a significantly increased risk for clinical complications (e.g., liver cirrhosis and hepatocellular carcinoma) and increased mortality.

Objective

What measures should be taken to reduce the high HCV-associated morbidity and mortality rates?

Results

New model calculations show that clinical complications of HCV infection can be prevented by using more effective therapies and increased rates of treatment, which can reduce liver-related mortality and all-cause mortality even with pre-existing cirrhosis. At the same time, an intensification of HCV screening programs is necessary.

Conclusions

With a consistent use of new methods of treating HCV, the HCV-associated disease burden in Germany can be significantly reduced in the next 15 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342

    Article  Google Scholar 

  2. Saraswat V, Norris S, Knegt RJ de et al (2015) Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2. J Viral Hepat 22:6–25

    Article  PubMed  Google Scholar 

  3. Poethko-Muller C, Zimmermann R, Hamouda O et al (2013) Epidemiology of hepatitis A, B, and C among adults in Germany. Results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56:707–715

    Article  CAS  PubMed  Google Scholar 

  4. Schlosser B, Domke D, Mockel M et al (2009) A prospective survey including 17,184 patients from a german metropolitan area reveals a high prevalence of chronic hepatitis C virus infection. Hepatology 50:670a–670a

    Google Scholar 

  5. Schlosser B, Domke D, Mockel M et al (2009) High prevalence of chronic Hepatitis C Virus (Hcv) infection in a German metropolitan area: a prospective screening analysing 7683 patients. J Hepatol 50:S156–S157

    Article  Google Scholar 

  6. Vermehren J, Schlosser B, Domke D et al (2012) High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients. PLoS One 7

  7. Heidrich B, Cetindere A, Beyaz M et al (2014) High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting. Eur J Gastroenterol Hepatol 26:1090–1097

    Article  CAS  PubMed  Google Scholar 

  8. Wolffram I, Petroff D, Batz O et al (2015) Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol

  9. Razavi H, Waked I, Sarrazin C et al (2014) The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 21(Suppl 1):34–59

    Article  PubMed  Google Scholar 

  10. Westbrook RH, Dusheiko G (2014) Natural history of hepatitis C. J Hepatol 61:S58–S68

    Article  PubMed  Google Scholar 

  11. El-Kamary SS, Jhaveri R, Shardell MD (2011) All-cause, liver-, and non-liver, related mortality among hepatitis C infected individuals in the general us population. Am J Epidemiol 173:S234–S234

    Google Scholar 

  12. Omland LH, Christensen PB, Krarup H et al (2011) Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study. PLoS One 6:e22476

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Omland LH, Krarup H, Jepsen P et al (2010) Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 53:36–42

    Article  PubMed  Google Scholar 

  14. Lee MH, Yang HI, Lu SN et al (2012) Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 206:469–477

    Article  PubMed  Google Scholar 

  15. Maasoumy B, Wedemeyer H (2012) Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 26:401–412

    Article  PubMed  Google Scholar 

  16. Goossens N, Negro F (2014) Is Genotype 3 of the hepatitis C virus the new villain? Hepatology 59:2403–2412

    Article  CAS  PubMed  Google Scholar 

  17. Meer AJ van der (2015) Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 64:364–366

    Article  PubMed  Google Scholar 

  18. Deuffic-Burban S, Deltenre P, Buti M et al (2012) Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 143:974−+

    Article  PubMed  Google Scholar 

  19. Razavi H, ElKhoury AC, Elbasha E et al (2013) Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 57:2164–2170

    Article  PubMed Central  PubMed  Google Scholar 

  20. D’Ambrosio R, Aghemo A, Rumi MG et al (2012) A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56:532–543

    Article  Google Scholar 

  21. Marcellin P, Gane E, Buti M et al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381:468–475

    Article  CAS  PubMed  Google Scholar 

  22. Veldt BJ, Heathcote EJ, Wedemeyer H et al (2007) Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147:677–684

    Article  PubMed  Google Scholar 

  23. Meer AJ van der, Veldt BJ, Feld JJ et al (2012) Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308:2584–2593

    Article  PubMed  Google Scholar 

  24. Meer AJ van der, Wedemeyer H, Feld JJ et al (2014) Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 312:1927–1928

    Article  PubMed  Google Scholar 

  25. Hill AM, Saleem J, Heath KA, Simmons B (2014) Effects of Sustained Virological Response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with Hepatitis C infection. Hepatology 60:218a–219a

    Article  Google Scholar 

  26. Wedemeyer H (2015) Towards interferon-free treatment for all HCV genotypes. Lancet

  27. Wedemeyer H, Duberg AS, Buti M et al (2014) Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 21(Suppl 1):60–89

    Article  PubMed  Google Scholar 

  28. Flamm SL, Bacon BR, Dieterich D et al (2014) Evaluation of efficacy of sofosbuvir and simeprevir-based regimens in a real-life population of 345 HCV patients with cirrhosis; data from the TRIO network. Hepatology 60:677a–677a

    Article  Google Scholar 

  29. Smith BD, Morgan RL, Beckett GA et al (2012) Hepatitis C virus testing of persons born during 1945–1965: recommendations from the centers for disease control and prevention. Ann Intern Med 157:817−+

    Article  PubMed  Google Scholar 

  30. Rein DB, Smith BD, Wittenborn JS et al (2012) The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med156:263–270

    Article  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. S. Hardtke und H. Wedemeyer geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    S. Hardtke &  H. Wedemeyer

Authors
  1. S. Hardtke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Wedemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Wedemeyer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hardtke, S., Wedemeyer, H. Eradikation des Hepatitis-C-Virus und Verhinderung klinischer Endpunkte. Gastroenterologe 10, 305–309 (2015). https://doi.org/10.1007/s11377-015-0995-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11377-015-0995-7

Schlüsselwörter

Keywords

Search

Navigation